Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

ADMA Biologics

Nasdaq:ADMA
Snowflake Description

High growth potential with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ADMA
Nasdaq
$265M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. The last earnings update was 15 days ago. More info.


Add to Portfolio Compare Print
  • ADMA Biologics has significant price volatility in the past 3 months.
ADMA Share Price and Events
7 Day Returns
36.4%
NasdaqGM:ADMA
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-19%
NasdaqGM:ADMA
0%
US Biotechs
-11.5%
US Market
ADMA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ADMA Biologics (ADMA) 36.4% 5.1% -22.3% -19% -37.1% -66.8%
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • ADMA underperformed the Biotechs industry which returned 0% over the past year.
  • ADMA underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
ADMA
Industry
5yr Volatility vs Market
Related Companies

ADMA Value

 Is ADMA Biologics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ADMA Biologics. This is due to cash flow or dividend data being unavailable. The share price is $3.07.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ADMA Biologics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ADMA Biologics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:ADMA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.89
NasdaqGM:ADMA Share Price ** NasdaqGM (2020-03-27) in USD $3.07
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ADMA Biologics.

NasdaqGM:ADMA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ADMA Share Price ÷ EPS (both in USD)

= 3.07 ÷ -0.89

-3.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ADMA Biologics is loss making, we can't compare its value to the US Biotechs industry average.
  • ADMA Biologics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does ADMA Biologics's expected growth come at a high price?
Raw Data
NasdaqGM:ADMA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.46x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
62.8%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ADMA Biologics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ADMA Biologics's assets?
Raw Data
NasdaqGM:ADMA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.44
NasdaqGM:ADMA Share Price * NasdaqGM (2020-03-27) in USD $3.07
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:ADMA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ADMA Share Price ÷ Book Value per Share (both in USD)

= 3.07 ÷ 0.44

6.95x

* Primary Listing of ADMA Biologics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ADMA Biologics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess ADMA Biologics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ADMA Biologics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ADMA Future Performance

 How is ADMA Biologics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
62.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ADMA Biologics expected to grow at an attractive rate?
  • ADMA Biologics's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • ADMA Biologics's earnings growth is expected to exceed the United States of America market average.
  • ADMA Biologics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:ADMA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:ADMA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 62.8%
NasdaqGM:ADMA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 34.2%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:ADMA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:ADMA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 238 63 4
2023-12-31 194 45 45 5
2022-12-31 144 -4 15 5
2021-12-31 98 -2 -18 6
2020-12-31 54 -64 -39 6
2020-03-28
NasdaqGM:ADMA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 29 -76 -48
2019-09-30 21 -75 -56
2019-06-30 18 -64 -59
2019-03-31 16 -61 -61
2018-12-31 17 -63 -66
2018-09-30 18 -57 -61
2018-06-30 18 -54 -61
2018-03-31 17 -48 -55
2017-12-31 16 -37 -44
2017-09-30 14 -28 -35
2017-06-30 12 -22 -24
2017-03-31 11 -18 -21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ADMA Biologics's earnings are expected to grow significantly at over 20% yearly.
  • ADMA Biologics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:ADMA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from ADMA Biologics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ADMA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.78 1.22 0.45 4.00
2023-12-31 0.54 0.91 0.17 5.00
2022-12-31 0.19 0.40 0.00 5.00
2021-12-31 -0.20 0.09 -0.59 6.00
2020-12-31 -0.46 -0.16 -0.63 6.00
2020-03-28
NasdaqGM:ADMA Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.89
2019-09-30 -1.09
2019-06-30 -1.24
2019-03-31 -1.34
2018-12-31 -1.45
2018-09-30 -1.42
2018-06-30 -1.62
2018-03-31 -1.78
2017-12-31 -1.91
2017-09-30 -2.07
2017-06-30 -1.77
2017-03-31 -1.69

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ADMA Biologics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess ADMA Biologics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ADMA Biologics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ADMA Past Performance

  How has ADMA Biologics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ADMA Biologics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ADMA Biologics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ADMA Biologics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ADMA Biologics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ADMA Biologics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ADMA Biologics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ADMA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 29.35 -48.28 28.08 2.34
2019-09-30 21.37 -55.76 28.92 2.80
2019-06-30 18.38 -59.45 28.91 3.31
2019-03-31 16.47 -60.99 29.40 3.83
2018-12-31 16.99 -65.74 30.31 3.93
2018-09-30 17.93 -60.69 29.66 4.21
2018-06-30 18.43 -60.76 27.70 5.02
2018-03-31 17.17 -55.04 22.75 5.34
2017-12-31 15.76 -43.76 21.36 5.57
2017-09-30 14.09 -35.34 18.34 4.95
2017-06-30 12.29 -24.46 15.93 4.81
2017-03-31 11.17 -21.44 16.71 6.85
2016-12-31 10.66 -19.52 13.94 7.69
2016-09-30 9.85 -19.54 12.41 9.10
2016-06-30 8.76 -20.31 12.44 9.54
2016-03-31 7.80 -18.98 11.96 7.64
2015-12-31 7.18 -17.97 11.36 7.02
2015-09-30 6.15 -16.95 10.54 6.94
2015-06-30 5.67 -15.23 9.30 6.31
2015-03-31 5.86 -14.51 9.13 6.59
2014-12-31 5.92 -16.81 8.67 9.52
2014-09-30 4.85 -17.95 8.06 10.55
2014-06-30 4.59 -17.26 7.51 10.48
2014-03-31 3.84 -18.19 6.77 12.17
2013-12-31 3.07 -15.53 6.78 9.30
2013-09-30 3.17 -13.08 6.20 7.61
2013-06-30 2.42 -13.63 6.22 8.15
2013-03-31 1.91 -9.95 5.70 4.85

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ADMA Biologics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ADMA Biologics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ADMA Biologics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ADMA Biologics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ADMA Biologics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ADMA Health

 How is ADMA Biologics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ADMA Biologics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ADMA Biologics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ADMA Biologics's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of ADMA Biologics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ADMA Biologics Company Filings, last reported 2 months ago.

NasdaqGM:ADMA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 26.19 83.20 26.75
2019-09-30 36.12 82.74 48.01
2019-06-30 46.91 82.36 73.62
2019-03-31 10.04 55.77 16.53
2018-12-31 19.77 41.32 22.75
2018-09-30 37.21 41.02 42.37
2018-06-30 51.76 40.74 55.15
2018-03-31 23.03 40.47 26.12
2017-12-31 40.33 40.21 43.11
2017-09-30 12.99 29.37 13.60
2017-06-30 27.68 30.85 25.57
2017-03-31 -10.76 17.54 8.79
2016-12-31 -4.46 18.43 15.31
2016-09-30 -0.15 18.28 18.93
2016-06-30 3.92 18.09 23.82
2016-03-31 -3.37 14.43 11.62
2015-12-31 0.82 14.30 16.81
2015-09-30 4.91 14.17 20.94
2015-06-30 9.52 14.05 23.75
2015-03-31 13.43 14.95 28.08
2014-12-31 6.01 14.63 21.85
2014-09-30 9.24 9.93 20.27
2014-06-30 12.30 9.78 24.18
2014-03-31 15.90 9.75 28.72
2013-12-31 21.57 4.94 29.08
2013-09-30 -0.74 4.92 5.38
2013-06-30 1.73 4.90 7.65
2013-03-31 6.40 4.88 10.32
  • ADMA Biologics's level of debt (317.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (240.3% vs 317.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ADMA Biologics has less than a year of cash runway based on current free cash flow.
  • ADMA Biologics has less than a year of cash runway if free cash flow continues to grow at historical rates of 34.4% each year.
X
Financial health checks
We assess ADMA Biologics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ADMA Biologics has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ADMA Dividends

 What is ADMA Biologics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ADMA Biologics dividends.
If you bought $2,000 of ADMA Biologics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ADMA Biologics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ADMA Biologics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:ADMA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:ADMA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ADMA Biologics has not reported any payouts.
  • Unable to verify if ADMA Biologics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ADMA Biologics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ADMA Biologics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ADMA Biologics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ADMA Biologics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ADMA Biologics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ADMA Management

 What is the CEO of ADMA Biologics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Adam Grossman
COMPENSATION $1,553,300
AGE 42
TENURE AS CEO 8.4 years
CEO Bio

Mr. Adam S. Grossman is the Co-Founder of ADMA Biologics, Inc. and has been its Chief Executive Officer and President since October 2011 and 2007 respectively. Mr. Grossman serves as the President, Chief Executive Officer and Director of R&R Acquisition VI Inc. He served as the Chief Operating Officer of ADMA Biologics, Inc. from 2007 to October 2011. Mr. Grossman has over 20 years’ experience in the blood and plasma industry. He has experience in launching new products, building and managing national and international sales forces, managing clinical trials and completing numerous business development transactions. Prior to founding ADMA Biologics, Inc., Mr. Grossman served as the Executive Vice President of National Hospital Specialties and GenesisBPS from 1994 to 2011. Mr. Grossman is a control person of Areth, LLC. Mr. Grossman is the managing Member of Hariden. Previously, he worked at MedImmune, Inc., where he worked on marketing teams for RSV and CMV immunoglobulins and at the American Red Cross, where he launched new products with the Biomedical Services division. He has been a Director at ADMA Biologics, Inc. since 2007. Mr. Grossman holds a B.S. in Business Administration, with a specialization in International Business and Marketing, from American University.

CEO Compensation
  • Adam's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Adam's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the ADMA Biologics management team in years:

7.7
Average Tenure
59
Average Age
  • The average tenure for the ADMA Biologics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Adam Grossman

TITLE
Co-Founder
COMPENSATION
$2M
AGE
42
TENURE
8.4 yrs

Jerrold Grossman

TITLE
Co-Founder & Vice Chairman of the Board
COMPENSATION
$111K
AGE
71

Brian Lenz

TITLE
Executive VP & CFO
COMPENSATION
$940K
AGE
47
TENURE
7.8 yrs

James Mond

TITLE
Executive VP
COMPENSATION
$1M
AGE
73
TENURE
7.7 yrs

Kaitlin Kestenberg

TITLE
Vice President of Compliance

Mat Peters

TITLE
Vice President & General Counsel
TENURE
0.2 yrs

Michael Least

TITLE
Vice President of Sales & Commercial Operations

Drew Pantello

TITLE
Vice President of Marketing & Corporate Development

James Hauert

TITLE
Senior Vice President of Commercialization & Strategy
TENURE
4.7 yrs

Gene Wetzstein

TITLE
Executive Director & Head of Scientific Engagement
Board of Directors Tenure

Average tenure and age of the ADMA Biologics board of directors in years:

7.8
Average Tenure
56
Average Age
  • The tenure for the ADMA Biologics board of directors is about average.
Board of Directors

Steve Elms

TITLE
Chairman of the Board
COMPENSATION
$111K
AGE
56

Adam Grossman

TITLE
Co-Founder
COMPENSATION
$2M
AGE
42
TENURE
13.2 yrs

Jerrold Grossman

TITLE
Co-Founder & Vice Chairman of the Board
COMPENSATION
$111K
AGE
71
TENURE
8.4 yrs

Eric Richman

TITLE
Independent Director
COMPENSATION
$105K
AGE
58
TENURE
13.2 yrs

Dov Goldstein

TITLE
Independent Director
COMPENSATION
$91K
AGE
52
TENURE
13.2 yrs

Larry Guiheen

TITLE
Independent Director
COMPENSATION
$99K
AGE
68
TENURE
7.7 yrs

Bryant Fong

TITLE
Independent Director
COMPENSATION
$98K
AGE
46
TENURE
7.8 yrs

Roy Chemaly

TITLE
Member of Scientific Advisory Board
TENURE
5.8 yrs

John DeVincenzo

TITLE
Member of Scientific Advisory Board
TENURE
5.8 yrs

Jordan Orange

TITLE
Member of Scientific Advisory Board
TENURE
5.8 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by ADMA Biologics individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
23. Mar 20 Buy Perceptive Advisors LLC Company 19. Mar 20 19. Mar 20 500,000 $2.10 $1,050,000
11. Feb 20 Buy Perceptive Advisors LLC Company 11. Feb 20 11. Feb 20 4,563,700 $3.50 $15,972,950
11. Feb 20 Buy Jerrold Grossman Individual 11. Feb 20 11. Feb 20 45,714 $3.50 $159,999
11. Feb 20 Buy Adam Grossman Individual 11. Feb 20 11. Feb 20 85,714 $3.50 $299,999
11. Feb 20 Buy Lawrence Guiheen Individual 11. Feb 20 11. Feb 20 20,000 $3.50 $70,000
11. Feb 20 Buy James Mond Individual 11. Feb 20 11. Feb 20 4,285 $3.50 $14,998
11. Feb 20 Buy Brian Lenz Individual 11. Feb 20 11. Feb 20 7,142 $3.50 $24,997
07. Jun 19 Sell Biotest Divestiture Trust Company 06. Jun 19 06. Jun 19 -5,813,954 $3.75 $-21,802,328
23. May 19 Buy Perceptive Advisors LLC Company 21. May 19 21. May 19 4,000,000 $4.00 $16,000,000
21. May 19 Buy Adam Grossman Individual 17. May 19 17. May 19 30,000 $4.00 $120,000
21. May 19 Buy Jerrold Grossman Individual 17. May 19 17. May 19 12,000 $4.00 $48,000
21. May 19 Buy Lawrence Guiheen Individual 17. May 19 17. May 19 25,000 $4.00 $100,000
21. May 19 Buy James Mond Individual 17. May 19 17. May 19 4,500 $4.00 $18,000
21. May 19 Buy Brian Lenz Individual 17. May 19 17. May 19 5,000 $4.00 $20,000
X
Management checks
We assess ADMA Biologics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ADMA Biologics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ADMA News

Simply Wall St News

ADMA Company Info

Description

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also offers Nabi-HB, a hyperimmune globulin for the treatment of acute exposure; and Bivigam, an intravenous immune globulin for the treatment of primary humoral immunodeficiency. In addition, it operates source plasma collection facilities in Norcross, Marietta, and Kennesaw, Georgia. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Details
Name: ADMA Biologics, Inc.
ADMA
Exchange: NasdaqGM
Founded: 2004
$265,080,110
86,345,313
Website: http://www.admabiologics.com
Address: ADMA Biologics, Inc.
465 State Route 17,
Ramsey,
New Jersey, 07446,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ADMA Common Stock Nasdaq Global Market US USD 18. Oct 2013
Number of employees
Current staff
Staff numbers
314
ADMA Biologics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:23
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/26
Last earnings filing: 2020/03/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.